JP2021521776A5 - - Google Patents

Info

Publication number
JP2021521776A5
JP2021521776A5 JP2020556863A JP2020556863A JP2021521776A5 JP 2021521776 A5 JP2021521776 A5 JP 2021521776A5 JP 2020556863 A JP2020556863 A JP 2020556863A JP 2020556863 A JP2020556863 A JP 2020556863A JP 2021521776 A5 JP2021521776 A5 JP 2021521776A5
Authority
JP
Japan
Prior art keywords
seq
tcr
item
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020556863A
Other languages
English (en)
Japanese (ja)
Other versions
JP7469807B2 (ja
JP2021521776A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028239 external-priority patent/WO2019204683A1/en
Publication of JP2021521776A publication Critical patent/JP2021521776A/ja
Publication of JP2021521776A5 publication Critical patent/JP2021521776A5/ja
Priority to JP2024056106A priority Critical patent/JP7761293B2/ja
Application granted granted Critical
Publication of JP7469807B2 publication Critical patent/JP7469807B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020556863A 2018-04-19 2019-04-19 Mage-b2特異性を有するt細胞受容体およびその使用 Active JP7469807B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024056106A JP7761293B2 (ja) 2018-04-19 2024-03-29 Mage-b2特異性を有するt細胞受容体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862660083P 2018-04-19 2018-04-19
US62/660,083 2018-04-19
PCT/US2019/028239 WO2019204683A1 (en) 2018-04-19 2019-04-19 T cell receptors with mage-b2 specificity and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024056106A Division JP7761293B2 (ja) 2018-04-19 2024-03-29 Mage-b2特異性を有するt細胞受容体およびその使用

Publications (3)

Publication Number Publication Date
JP2021521776A JP2021521776A (ja) 2021-08-30
JP2021521776A5 true JP2021521776A5 (cg-RX-API-DMAC7.html) 2022-03-03
JP7469807B2 JP7469807B2 (ja) 2024-04-17

Family

ID=68239239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020556863A Active JP7469807B2 (ja) 2018-04-19 2019-04-19 Mage-b2特異性を有するt細胞受容体およびその使用
JP2024056106A Active JP7761293B2 (ja) 2018-04-19 2024-03-29 Mage-b2特異性を有するt細胞受容体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024056106A Active JP7761293B2 (ja) 2018-04-19 2024-03-29 Mage-b2特異性を有するt細胞受容体およびその使用

Country Status (7)

Country Link
US (2) US12202877B2 (cg-RX-API-DMAC7.html)
EP (1) EP3784255B1 (cg-RX-API-DMAC7.html)
JP (2) JP7469807B2 (cg-RX-API-DMAC7.html)
KR (1) KR102892744B1 (cg-RX-API-DMAC7.html)
CN (1) CN112236447B (cg-RX-API-DMAC7.html)
CA (1) CA3097399A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019204683A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA50819A (fr) 2014-12-23 2021-04-07 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
AU2021238582A1 (en) * 2020-03-16 2022-09-22 Biontech Cell & Gene Therapies Gmbh Antigen-specific T cell receptors and T cell epitopes
WO2021236638A1 (en) * 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
CN111718409B (zh) * 2020-06-17 2021-03-02 深圳豪石生物科技有限公司 一种t细胞受体及其应用
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022099297A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Multiplexed engineered ipsc and immune effector cells targeting solid tumors
US20250282887A1 (en) * 2021-04-02 2025-09-11 Amgen Inc. Mageb2 binding constructs
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304657A1 (en) 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
US9345748B2 (en) 2010-09-21 2016-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SSX-2 T cell receptors and related materials and methods of use
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
SI2755997T1 (sl) * 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
US9879065B2 (en) 2012-09-14 2018-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing MHC class II-restricted MAGE-A3
EP3231864B1 (en) * 2014-12-11 2024-07-31 Riken Modified immunocyte, method for producing modified immunocyte and utilization thereof
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
MX2018012265A (es) * 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
KR20190065189A (ko) 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체
KR102397771B1 (ko) * 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
KR20190062505A (ko) 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
AU2018231405B2 (en) * 2017-03-07 2024-02-08 Universität Basel MR1 restricted T cell receptors for cancer immunotherapy
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.

Similar Documents

Publication Publication Date Title
US20250171560A1 (en) Chimeric antigen receptor cells for treating solid tumor
EP3615565B1 (en) Tcr and peptides
AU2025205077A1 (en) Methods for enhancing efficacy of therapeutic immune cells
EP3177314B1 (en) T cell immunotherapy specific for wt-1
JP2024074861A (ja) Mage-b2特異性を有するt細胞受容体およびその使用
US20190119350A1 (en) Ny-eso-1 specific tcrs and methods of use thereof
SG11202110171QA (en) Mage a4 t cell receptors
EP3095792A1 (en) T cell receptor with specificity for myeloperoxidase peptide and uses thereof
RU2018135097A (ru) Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине
US20210379149A1 (en) Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
US11161913B2 (en) Chimeric antigen receptor cells for treating solid tumor
CA3117272A1 (en) Tcr and peptides
US20210340201A1 (en) Immunotherapy targeting kras or her2 antigens
US20240270813A1 (en) T CELL RECEPTORS (TCRs) TARGETING MINOR HISTOCOMPATIBILITY ANTIGEN HA-1
Geiger et al. New approaches for the immunotherapy of acute myeloid leukemia
JP7558935B2 (ja) メソテリンを標的とする免疫療法
JP2022505107A5 (cg-RX-API-DMAC7.html)
JP2023526416A5 (cg-RX-API-DMAC7.html)
US20230133564A1 (en) Cd3-fusion protein and uses thereof
CN113929767A (zh) 具有高亲和力的t细胞受体及其用途
JP2022554349A5 (cg-RX-API-DMAC7.html)
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
HK40113193A (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
WO2024243807A1 (zh) 靶向ny-eso-1的高亲和力t细胞受体及其应用
JP2026516201A (ja) 急性骨髄性白血病(aml)の標的化免疫療法のための方法